Patient Name : MRS.

TEJASHRI DIVEKAR
Client Name : TRU TRUSTED DIAGNOSTIC
Age/Gender : 25 years / Female
Collected On : 20/01/2024, 08:51 PM
Sample Type : SERUM MEDID : 113193
Received On : 20/01/2024, 10:02 PM
Sample ID : AA5433967
Reported On : 21/01/2024, 03:02 PM
Ref. Doctor : SELF
SPECIALITY - BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

QUAD MARKER WITH GRAPH

Quad Marker Test
SECOND TRIMESTER RISK ESTIMATE
(Method: Risk calculation by PRISCA 5.0.2.13 / 15 software)
Down syndrome (T21) Risk Estimate 1:7923 High Risk : < 1:250
Low Risk : > 1:250

Down syndrome (T21) Risk assessment Risk for Trisomy 21 is below the cut off which represents a low risk.

Trisomy 18 Risk Estimate 1:10000 High Risk : < 1:100

Low Risk : > 1:100
Trisomy 18 Risk assessment Risk for Trisomy 18 is below the cut off which represents a low risk.
Neural Tube Defects (NTD) Risk 0.74 High Risk : > 2.5
Low Risk : < 2.5
Neural Tube Defects assessment MoM AFP (0.74) is located in the low risk area for neural tube defects.
Down syndrome(T21) Maternal Age Risk 1:1321

Additional Information T21-TRISOMY 21 T13/18-TRISOMY 13/18

> QUADTRIPLE MARKER serum screening has become 2 standard tool used in obstetrical care to identify pregnancies that may have a n increased risk for certain birth

defects, including neural tube defects (NTDs), Down syndrome, and Trisomy 18. The screen is performed by measuring analytes in matemal serum that are produced by the

fetus and the placenta. The analyte values along with matemal information such as age, weight, gestational age, diabetic status, and race are used together in a mathematical

model to derive arisk estimate with detectionrate 60— 80 % andincreases with age.

> The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician. Please note that risk calculations are statistical approaches

andhaveno diagnostic value!

> The patient combined risk presumes the NT measurement was done according to accepted guidelines (Prenat Diagn 18:51:523 (1989) The laboratory cannot be

holdresponsible for their impact ontherisk assessment!

> In twin pregnancies with a fetal demise, results may be unreliable, Results are not available for pregnancies with triplets and higher-cordermultiples.

> Prenatal screen is not a diagnostic test and a negative test does not necessarily rule out the absence of fetal defects and a positive test does not confirm Trisomy. Hence a

high risk report should be followed by confirmatory tests like Chorionic Villous Sampling (CVS) based on the clinical history.

This is an electronically authenticated report. Report Printed Date: 22/01/2024, 03:08 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 1 of 5
 Patient Name : MRS. TEJASHRI DIVEKAR
Client Name : TRU TRUSTED DIAGNOSTIC
Age/Gender : 25 years / Female
Collected On : 20/01/2024, 08:51 PM
Sample Type : SERUM MEDID : 113193
Received On : 20/01/2024, 10:02 PM
Sample ID : AA5433967
Reported On : 21/01/2024, 03:02 PM
Ref. Doctor : SELF
SPECIALITY - BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Alpha Fetoprotein(AFP)-Serum 48.95 ng/mL < 5.3 : Non pregnant

(Method: Chemiluminescence)
Pregnant : Gestational
Woman Age(wks)

24.9 : 15

28.5 : 16

32.6 : 17

37.2 : 18

42.5 : 19

48.6 : 20

MoM for Alpha Fetoprotein(AFP) 0.74 High Risk : > or = 2.50

(Method: Calculation) Low Risk : < 2.50
Beta Human Chorionic Gonadotropin Hormone 19356 mIU/mL < 5 : NEGATIVE
(Method: Chemiluminescence)

GESTATIONAL GESTATIONAL
LMP BETA HCG VALUE LMP BETA HCG VALUE
AGE AGE

(Weeks) (mIU/ml) (Weeks) (mIU/ml)

1.3 - 2 3.3 - 4 16 - 156 6-7 8-9 27,300 - 233,000

2-3 4-5 101 - 4,870 7 - 11 9 - 13 20,900 - 291,000

3-4 5-6 1,110 - 31,500 11 - 16 13 - 18 6,140 - 103,300

4-5 6-7 2,560 - 82,300 16 – 21 18 - 23 4,720 - 80,100

5-6 7-8 23,100 - 151,000 21 - 39 23 - 41 2,700 - 78,100

NOTE: The above Given Risk Level Interpretation is not age specific and is an information resource only and is not to be used or relied on for any diagnostic or treatment

purposes and should not be used as a substitute for professional diagnosis and treatment. Kindly Correlate clinically.

This is an electronically authenticated report. Report Printed Date: 22/01/2024, 03:08 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 2 of 5
 Patient Name : MRS. TEJASHRI DIVEKAR
Client Name : TRU TRUSTED DIAGNOSTIC
Age/Gender : 25 years / Female
Collected On : 20/01/2024, 08:51 PM
Sample Type : SERUM MEDID : 113193
Received On : 20/01/2024, 10:02 PM
Sample ID : AA5433967
Reported On : 21/01/2024, 03:02 PM
Ref. Doctor : SELF
SPECIALITY - BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

MoM for Beta HCG 0.78 High Risk : > or = 2.50

(Method: Calculation) Low Risk : < 2.50
Estriol Unconjugated (uE3) 1.32 ng/mL Non-pregnant females : <0.25 ng/mL -
(Method: Chemiluminescence) Gestational Age in Weeks
0.3 0– 1.05 : 16 – 17
0.63 – 2.30 : 18 - 26
2.90- 16.00 : 27 – 29
4.10 – 19.90 : 30 - 31
5.10 – 24.40 : 32 - 33

MoM for Estriol(E3) 1.00 High Risk : > or = 2.50

(Method: calculation) Low Risk : < 2.50
Inhibin A 229.65 pg/mL Mid cycle (Day 0) : 90-151
(Method: Enzyme Immuno-assay) Early Luteal (1 to 3 days) : 29-209
Mid Luteal (4 to 11 days) : 9-213
Late Luteal (12 to 14 days) : 5.9-26
Post-Menopausal (54-74 years) :
0.0-5.24

Age/Phase Inhibin A (Dimer) pg/mL

NORMAL CYCLING FEMALES NORMAL CYCLING FEMALES

Early Follicular Phase (-14 to -10) 1.8 – 17.3

Mid Follicular Phase (-9 to -4) 3.5 – 31.7

Late Follicular Phase (-3 to -1) 9.8 – 90.3

Mid Cycle (Day 0) 16.9 – 91.8

Early Luteal (4 to 11) 16.1 – 97.5

This is an electronically authenticated report. Report Printed Date: 22/01/2024, 03:08 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 3 of 5
 Patient Name : MRS. TEJASHRI DIVEKAR
Client Name : TRU TRUSTED DIAGNOSTIC
Age/Gender : 25 years / Female
Collected On : 20/01/2024, 08:51 PM
Sample Type : SERUM MEDID : 113193
Received On : 20/01/2024, 10:02 PM
Sample ID : AA5433967
Reported On : 21/01/2024, 03:02 PM
Ref. Doctor : SELF
SPECIALITY - BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Mid Luteal (4 to 11) 3.9 – 87.7

Late Luteal (12 to 14) 2.7 – 47.1

IVF-Peak Levels 354.2 – 1690.0

PCOS-Ovulatory 5.7 – 16.0

Postmenopausal Less than 6.9

Normal males Less than 2.1

Gestational Age (Weeks) Inhibin A (pg/ml)

15 162.80 to 208.20

16 154.97 to 187.21

17 140.45 to 178.40

18 149.76 to 194.20

19 124.60 to 213.90

20 139.20 to 232.60

21 135.10 to 263.60

22 106.00 to 357.00

MoM for Inhibin-A 0.88

(Method: Calculation)

PATIENT DEMOGRAPHICS
Weight : 50
Date of birth : 27.jun 1998

This is an electronically authenticated report. Report Printed Date: 22/01/2024, 03:08 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 4 of 5
 Patient Name : MRS. TEJASHRI DIVEKAR
Client Name : TRU TRUSTED DIAGNOSTIC
Age/Gender : 25 years / Female
Collected On : 20/01/2024, 08:51 PM
Sample Type : SERUM MEDID : 113193
Received On : 20/01/2024, 10:02 PM
Sample ID : AA5433967
Reported On : 21/01/2024, 03:02 PM
Ref. Doctor : SELF
SPECIALITY - BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

H/O Diabetes : Not provided

H/O IVF : Not provided
Origin : Asian
Date of scan : 20.jan 2024
No of fetus : Single
MoM for NT : Not applicable
Interpretation:
*The estimated risk calculations and screen results are dependent on accurate information for gestation, maternal age, and weight. Inaccurate information canleadto significant

alterations in the estimatedrisk.

*In twin pregnancies, the risk for Down syndrome is approximated, using twin-adjusted medians. A specific risk for Trisomy 18 cannot be calculated; therefore, results for

Tzisomy 18 are reported as either screen-negative or screen-positive. Risks for triplets and higher multiples cannot be calculated.

*Upon receiving maternal serum screening results, all information used in the risk calculation should be reviewed for accuracy (e.g., maternal date of birth, demographics,

sonographic information). If any information is incorrect, the laboratory should be contacted for a recalculation ofthe estimatedrisks.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 22/01/2024, 03:08 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 5 of 5
 Result Down's syndrome screening
Name Sample ID AA5433967 diabetes unknown
Mrs. TEJASHRI DIVEKAR D.O.B. 27/06/98 Fetuses 1
Patient ID 686314 Age at delivery 26.0 Smoker unknown
Day of serum taking 21/01/24 Weight [kg] 50 kg IVF unknown
Date of report: 21/01/24 Ethnic origin Asian
Previous trisomy 21 unknown
pregnancies

Corrected MoM's and calculated risks

AFP 48.95 ng/mL 0.74 Corr. MoM Gestational age at sample date 18 + 4
uE3 1.32 ng/mL 1.00 Corr. MoM determination method BPD Hadlock
HCG 19356 mIU/mL 0.78 Corr. MoM Physician
Inh-A 229.65 pg/mL 0.88 Corr. MoM
Risk
1:10
Tr.21 risk
at term

1:7923
1:100

1:250 Cut off

Age risk
at term
1:1000
1:1321
1:10000
13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 Age

Down's Syndrome Risk

The calculated risk for Trisomy 21 is below the cut off which represents a low risk.
After the result of the Trisomy 21 test it is expected that among 7923 women with the same data, there is one woman
with a trisomy 21 pregnancy and 7922 women with not affected pregnancies.
The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician.
Please note that risk calculations are statistical approaches and have no diagnostic value!

Neural tube defects risk Risk for trisomy 18

The corrected MoM AFP (0.74) is located in the low The calculated risk for trisomy 18 is < 1:10000, which
risk area for neural tube defects. indicates a low risk.

below cut off Below Cut Off, but above Age Risk above cut off Prisca 5.2.0.13